NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: University of California, Los Angeles
Conditions: Methamphetamine-dependence, Rectal Gonorrhea, Rectal Chlamydia
Interventions: Contingency Management
Countries: United States
This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. The proposed trial will consist of 40 MSM, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. Following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.
Sex: MALE
Age: 18 Years to —
Healthy volunteers: Yes
Study type: INTERVENTIONAL
Inclusion Criteria: * Cisgender male * 18 years of age or older * Understand written and spoken English * Condomless receptive anal intercourse in past 90 days * Meet DSM-5 criteria for methamphetamine use disorder * Positive urine toxicology screen for MA metabolites at study entry * Negative rectal GC/CT screen (n=20) or Positive rectal GC and/or CT screen (n=20) * Able to provide written informed consent and willing/able to complete study visits. Exclusion Criteria: * Reports current treatment for another substance use disorder * Positive test for opioids, cocaine, and/or hallucinogens * Treatment for gonorrhea and/or chlamydia infection in past 3 months * Presence of a condition that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
- Los Angeles, California, United States